PODD

Insulet Corp

Investor Moves

NameValueActionChangePriceLast Price
Ken GriffinCitadel Advisors
$54M258.4k shares
TrimQ1 2026
$16M
$251.31
$167.65
Ray DalioBridgewater Associates
$7M35.3k shares
TrimQ1 2026
$9M
$251.31
$167.65
Paul Tudor Jones IITudor Investment
$-6.8M
ExitQ1 2026
$7M
$251.31
$167.65
Steven CohenPoint72
$671k3.2k shares
TrimQ1 2026
$1M
$251.31
$167.65
Ron BaronBaron Capital
$2M11.2k shares
AddQ1 2026
$115k
$251.31
$167.65
Jim SimonsRenaissance Technologies
$89M426k shares
AddQ1 2026
$3M
$251.31
$167.65

Congress Trades

NameValueActionAmount RangePriceLast Price
Ro KhannaDemocrat
$8k
BuyMay 1, 2026
$1k-$15k
--
$167.65

Insider Trades

NameValueActionPriceLast Price
Stonesifer Timothy C.Director
$400k2.8k shares
BuyJun 3, 2026
$143.51
$167.65
Borio LucianaDirector
$60k418 shares
SellJun 3, 2026
$143.27
$167.65
Minogue Michael RDirector
$500k2k shares
BuyFeb 25, 2026
$246.23
$167.65
McEvoy AshleyDirector, Officer: President And CEO
$1M4.3k shares
BuyFeb 20, 2026
$239.35
$167.65

News

seekingalpha.comInsulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)seekingalpha.comJun 8gurufocus.comInsulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Caregurufocus.comJun 6zacks.comWhy Is Insulet (PODD) Down 8.7% Since Last Earnings Report?zacks.comJun 5fool.comDexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?fool.comJun 4businesswire.comInsulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessionsbusinesswire.comJun 4